Drugs / Magnesium L-lactate dihydrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03567824 | Mar 2026 → Apr 2028 expected | — | Pharmalyte Solutions LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium L-lactate dihydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03567824 ↗ |
| Known as | MLD10 | “MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.” NCT03567824 ↗ |